Since their inception in Oxford in 2015, Panacea has been pivotal in the formation of over 400 companies, propelling their top 60 to a combined valuation of approximately £1.5Bn. Their unique blend of comprehensive R&D, commercialisation support, and essential funding transforms promising ideas into viable, successful enterprises.
Exclusive Support and Investment Opportunities
Panacea are committed to advancing health-related innovations, from early-stage ideas to ready-for-market products. Their equity-free programs offer significant benefits: up to £100k in prizes, complimentary lab space, and wide-ranging support in scientific, clinical, financial, and legal aspects. The standout companies gain priority access to pre-seed and seed investments through Panacea Ventures.
Distinguishing Panacea Stars is our robust network of over 200 C-suite mentors from leading entities like AstraZeneca, GSK, AbbVie, Novo Nordisk, IBM, Bio-Rad, Taylor Wessing, J A Kemp, and McKinsey & Co. These mentors, poised to join company boards, along with support from esteemed funding bodies such as Cancer Research UK and the British Heart Foundation, significantly amplify our participants’ development and success.
Join Our Develop Autumn/Winter 2024/25 Cohort
Panacea invite the next wave of innovators to their equity-free Develop Programme Autumn/Winter 2024/25 cohort.
| Application Deadline |
21/10/2024 |
| Event type |
Hybrid |
| Application required? |
Apply Here |
